Akèy › Histiyositoz selil Langerhans
Etid klinik pou Histiyositoz selil Langerhans ap rekrite nan Etazini
8 etid pou Histiyositoz selil Langerhans ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
Pa eta
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
Ap rekriteFaz 2
180 Days – 22 Years · Tout sèks · Mizajou Oct 2, 2026 · NCT05828069Mirdametinib in Histiocytic Disorders
Ap rekriteFaz 2
Laj 2 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT06153173Histiocytic Disorder Follow-up Study
Ap rekriteEtid obsèvasyon
Laj 0 a 89 · Tout sèks · Mizajou Jun 12, 2026 · NCT05915208Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
Ap rekriteFaz 2
Laj 1 a 30 · Tout sèks · Mizajou Apr 7, 2026 · NCT06582745Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jan 8, 2026 · NCT03329274Q702 for the Treatment of Patients With Hematologic Malignancies
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 10, 2025 · NCT06712810Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
Ap rekriteFaz 2
Tout laj · Tout sèks · Mizajou Sep 18, 2025 · NCT04079179Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
Ap rekriteFaz 3
Jiska laj 21 · Tout sèks · Mizajou Sep 11, 2025 · NCT02670707Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.